EUCTR2019-001687-30-DE进行中（未招募）1 期
A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed,in EGFR mutant non-small cell lung carcinoma with acquired resistance - ABC-lung
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Chemotherapy naïve, non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or IV. Patients who have received previous adjuvant or neoadjuvant chemotherapy are eligible if the date of last dose of treatment was at least 12 months before randomisation
- •- Known EGFR mutations genotypes by tissue or ctDNA; patients with common mutations (L858R or Del19) and other rare mutations (e.g. S768I, G719X) are eligible
- •- Measurable or evaluable disease by RECIST v1.1
- •- Disease progression (during or after) or unacceptable side effects from prior treatment with at least one EGFR TKI (TKI washout period = 7 days). If most recent line of treatment (1st or 2nd line) was a third-generation EGFR TKI (e.g. osimertinib):
- •– Patient must be known to be EGFR mutation positive, either on fresh tumour biopsy taken >7 days prior to protocol treatment start or by recent ctDNA analysis (informative ctDNA
- •test, local test).
- •– T790M genotype is allowed.
- •If most recent line of treatment (1st or 2nd line) was a first- or second-generation EGFR TKI (e.g. afatinib, dacomitinib, erlotinib, gefitinib):
- •– Patient must be known to be tissue EGFR T790M wild type (local test) on most recent line of EGFR TKI or if no tissue re-biopsy, no evidence of T790M on ctDNA but identified L858R, del19, S768I or G719X genotypes (informative ctDNA test, local test).
- •- Treatment with an EGFR TKI therapy for at least 30 days
- •- Adequate haematological, renal and liver function (CrCl at least 45ml/min)
- •- Willing to make available surplus tissue obtained at the time of acquired resistance to EGFR TKI
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •- Prior systemic cytotoxic chemotherapy for advanced stage NSCLC
- •- Prior therapy with bevacizumab or other anti-angiogenic agent
- •- Prior immune checkpoint inhibitor therapy
- •- More than two lines of EGFR TKI therapy
- •- Known small-cell lung carcinoma (SCLC) or high grade neuroendocrine carcinoma (if progression biopsy has been performed locally)
- •- Squamous cell histologic subtype
- •- Known EGFR T790M positive genotype by tissue on most recent EGFR TKI progression or ctDNA and have not received an approved EGFR TKI targeting T790M
- •- Active or untreated CNS metastases as determined by brain MRI
- •- Patients with CNS metastases must be non-progressive by RECIST v1.1 and symptomatically stable with no ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed.
- •- Radiotherapy in target lesions within 4 weeks of randomization
- •- QTc of grade =3 according to CTCAE v5.0
- •- Active autoimmune disease that has required systemic treatment in past 2 years
- •- Active or uncontrolled HIV, tuberculosis, hepatitis B or C infection
- •- Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or
- •diastolic blood pressure >100 mmHg). Anti-hypertensive therapy to achieve these parameters
- •is allowable.
- •- Prior history of hypertensive crisis or hypertensive encephalopathy
- •- Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to randomization
- •- History of haemoptysis (>=2.5 ml of bright red blood per episode) within 1 month prior to randomization
- •- Recent surgery: Core biopsy or other minor surgical procedure, excluding placement of a
- •vascular access device, within 7 days prior to the first dose of bevacizumab:
- •- Major surgery of significant traumatic injury within 28 days prior to the first dose of bevacizumab
- •- Minor surgical procedures within 7 days, or placement of vascular access device 2 days prior to the first dose of bevacizumab
- •- Serious, non-healing wound, active ulcer, or untreated bone fracture
- •- Proteinuria, as demonstrated by urine dipstick or >1.0 g of protein in a 24-hour urine collection
- •- Any unresolved toxicities from prior therapy greater than CTCAE v5.0 grade 1 at the time of starting trial treatment with the exception of Alopecia
- •- History of active diverticulitis
研究者
相似试验
进行中（未招募）
1 期
A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR geneChemotherapy naïve, EGFR mutant non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or IV.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001687-30-ESEuropean Thoracic Oncology Platform (ETOP)95
招募中
不适用
A ClinicalI trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR mutant non-small cell lung carcinoma with acquired resistanceKCT0005588Yonsei University Health System, Severance Hospital30
进行中（未招募）
1 期
A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. TRIFOUR study”.nresectable locally advanced or metastatic triple negative breast cancer.MedDRA version: 23.0Level: LLTClassification code 10084066Term: Triple negative breast cancer metastaticSystem Organ Class: 100000004864EUCTR2021-003402-46-ESCantargia AB116
进行中（未招募）
1 期
A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. TRIFOUR studyAdvanced triple negative breast cancerMedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864CTIS2024-512052-38-00Cantargia AB117
已完成
2 期
Clinical trial on trial on eraippu erumal with yoga therapyCTRI/2019/06/019754S MUTHU VIGNESH40